Abstract:Thiazolidinediones (TZDs) (e.g. pioglitazone and rosiglitazone), known insulin sensitiser agents for type II diabetes mellitus, exhibit controversial effects on cardiac tissue. Despite consensus on their association with increased heart failure risk, limiting TZD use in diabetes management, the underlying mechanisms remain uncharacterised. Herein, we report a comprehensive in vitro investigation utilising a novel toxicoproteomics pipeline coupled with cytotoxicity assays in human adult cardiomyocytes to elucidate mechanistic insights into TZD cardiotoxicity. The cytotoxicity assay findings showed a significant loss of mitochondrial adenosine triphosphate production upon exposure to either TZD agents, which may underpin TZD cardiotoxicity. Our toxicoproteomics analysis revealed that mitochondrial dysfunction primarily stems from oxidative phosphorylation impairment, with distinct signalling mechanisms observed for both agents. The type of cell death differed strikingly between the two agents, with rosiglitazone exhibiting features of caspase‐dependent apoptosis and pioglitazone implicating mitochondrial‐mediated necroptosis, as evidenced by the protein upregulation in the phosphoglycerate mutase family 5–dynamin‐related protein 1 axis. Furthermore, our analysis revealed additional mechanistic aspects of cardiotoxicity, showcasing drug specificity. The downregulation of various proteins involved in protein machinery and protein processing in the endoplasmic reticulum was observed in rosiglitazone‐treated cells, implicating proteostasis in the rosiglitazone cardiotoxicity. Regarding pioglitazone, the findings suggested the potential activation of the interplay between the complement and coagulation systems and the disruption of the cytoskeletal architecture, which was primarily mediated through the integrin‐signalling pathways responsible for pioglitazone‐induced myocardial contractile failure. Collectively, this study unlocks substantial mechanistic insight into TZD cardiotoxicity, providing the rationale for future optimisation of antidiabetic therapies.

Thiazolidinediones Protect Mouse Pancreatic Β-Cells Directly from Cytokine-Induced Cytotoxicity Through PPARγ-dependent Mechanisms

[Inhibitory Effects of Thiazolidinedione Upon Cytokine-Induced Apoptosis in Pancreatic Beta-Cell Line].

Glitazones Protects Beta Cell Function from Cytotoxic Cytokines Through PPAR Gammadependent Mechanisms

Ginsenoside Rg1 Improves Inflammation and Autophagy of the Pancreas and Spleen in Streptozotocin-Induced Type 1 Diabetic Mice.

Protective effect of pioglitazone on islet cell apoptosis induced by proinflammatory cytokines

Epigallocatechin-3-gallate Protects Pro-Inflammatory Cytokine Induced Injuries in Insulin-Producing Cells Through the Mitochondrial Pathway.

Cytotoxicity and toxicoproteomics analysis of thiazolidinedione exposure in human‐derived cardiomyocytes

Protective effects of pioglitazone on vascular endothelial cell dysfunction induced by high glucose via inhibition of IKKα/β-NFκB signaling mediated by PPARγ in vitro.

PPAR-gamma Knockout in Pancreatic Epithelial Cells Abolishes the Inhibitory Effect of Rosiglitazone on Caerulein-Induced Acute Pancreatitis.

Effects of thiazolidinediones on protection of the kidney

Activation of PPARβ/δ Protects Pancreatic Β Cells from Palmitate-Induced Apoptosis by Upregulating the Expression of GLP-1 Receptor.

Histone Deacetylase Inhibitor MGCD0103 Protects the Pancreas from Streptozotocin-Induced Oxidative Stress and Β-Cell Death

Protection of Pioglitazone for Diabetes Mellitus Beyond Its Hypoglycemic Effect

NAG-1/GDF15 protects against streptozotocin-induced type 1 diabetes by inhibiting apoptosis, preserving beta-cell function, and suppressing inflammation in pancreatic islets

Activated PPAR beta/delta Protects Pancreatic beta Cells in Type 2 Diabetic Goto-Kakizaki Rats from Lipoapoptosis via GPR40

Pharmacological Activation of PPAR Gamma Ameliorates Vascular Endothelial Insulin Resistance Via a Non-Canonical PPAR Gamma-Dependent Nuclear Factor-Kappa B Trans-Repression Pathway.

Paeoniflorin Protects Pancreatic Β Cells from STZ-induced Damage Through Inhibition of the P38 MAPK and JNK Signaling Pathways

Activated PPARβ/δ Protects Pancreatic β Cells in Type 2 Diabetic Goto-Kakizaki Rats from Lipoapoptosis via GPR40.

Irisin suppresses pancreatic β cell pyroptosis in T2DM by inhibiting the NLRP3-GSDMD pathway and activating the Nrf2-TrX/TXNIP signaling axis

Pioglitazone Suppresses the Lipopolysaccharide-Induced Production of Inflammatory Factors in Mouse Macrophages by Inactivating Nf-Kappa B

IGF-1 ameliorates streptozotocin-induced pancreatic β cell dysfunction and apoptosis via activating IRS1/PI3K/Akt/FOXO1 pathway